S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)

Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

$3.95
+0.06 (+1.54%)
(As of 10:21 AM ET)
Today's Range
$3.91
$4.00
50-Day Range
$3.47
$4.61
52-Week Range
$3.30
$7.00
Volume
261,313 shs
Average Volume
961,521 shs
Market Capitalization
$227.28 million
P/E Ratio
79.02
Dividend Yield
N/A
Price Target
N/A

Vanda Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
5.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
1.89mentions of Vanda Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.01 to ($0.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.16 out of 5 stars

Medical Sector

560th out of 939 stocks

Pharmaceutical Preparations Industry

263rd out of 434 stocks

VNDA stock logo

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Stock Price History

VNDA Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
VNDA Sep 2024 3.000 put
VNDA Sep 2024 3.000 call
Q4 2023 Vanda Pharmaceuticals Inc Earnings Call
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
203
Year Founded
2002

Profitability

Net Income
$2.51 million
Pretax Margin
3.29%

Debt

Sales & Book Value

Annual Sales
$192.64 million
Book Value
$9.47 per share

Miscellaneous

Free Float
53,107,000
Market Cap
$223.83 million
Optionable
Optionable
Beta
0.77

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed in 2024?

Vanda Pharmaceuticals' stock was trading at $4.22 at the start of the year. Since then, VNDA shares have decreased by 5.9% and is now trading at $3.97.
View the best growth stocks for 2024 here
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings results on Wednesday, February, 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The biopharmaceutical company earned $45.27 million during the quarter, compared to analysts' expectations of $37 million. Vanda Pharmaceuticals had a net margin of 1.30% and a trailing twelve-month return on equity of 0.46%.

What ETFs hold Vanda Pharmaceuticals' stock?

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE),

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.01%), Vanguard Group Inc. (6.01%), Dimensional Fund Advisors LP (3.42%), Nantahala Capital Management LLC (1.76%), Federated Hermes Inc. (1.42%) and GSA Capital Partners LLP (0.99%). Insiders that own company stock include Aranthan Jones II, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VNDA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners